摘要
目的观察惠迪肠溶片对风湿病患者体内可溶性细胞间黏附分子-l和可溶性选择素E血清水平的影响,以评价惠迪肠溶片治疗风湿病的临床疗效。方法采用自身前后对照,纳入自身免疫性风湿病[本研究含系统性红斑狼疮(SLE)、类风湿关节炎(RA)、多发性肌炎/皮肌炎(PM/DM)病例]口服惠迪肠溶片,每次2片,每日3次,观察期为3个月。测定治疗前后的血清sICAM-1和sE-selectin含量。结果自身免疫性风湿病患者经惠迪肠溶片治疗后,血清sICAM-1和sE-selectin含量显著降低(P<0.05)。结论惠迪肠溶片能降低自身免疫性风湿病患者血清sICAM-1和sE-selectin水平,从而减轻自身免疫引起的自身损害,对自身免疫性风湿病有治疗作用。
Objective To study the effects of Huidi mesalazine in patients with autoimmune rheumatic disease. Methods The level of sICAM-1 and sE-selectin in the blood sera of patients with rheumatic disease（SLE,RA,PM/DM） was tested by ELISA, after the patients treated to Huidi mesalazine, compared with the self-concentration untreated. Results The concentrations of sICAM-1 and sE-selectin in all three group patients were signiifcantly lower, compared to the concentrations untreated （P〈0.05）. Conclusion Huidi mesalazine can reduce the concentrations of sICAM-1 and sE-selectin in the sera of patients with autoimmune rheumatic disease.
出处
《中国医药指南》
2013年第25期1-2,共2页
Guide of China Medicine
